Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan hospital praises deep-brain stimulation for Parkinson's:

This article was originally published in Clinica

Executive Summary

Deep brain stimulation (DBS) is reportedly achieving a 100% success rate in patients with Parkinson's disease being treated at Taiwan's Buddhist Tzu Chi General Hospital, in Hualien. The claim is made by Chen Hsin-Yuan, director of the hospital's Parkinson's treatment and research centre. All 110 patients treated at the hospital (accounting for 44% of all DBS procedures in Taiwan, according to the China Post) have benefited from the method, he claims, arguing that it is the best treatment for patients whose symptoms are not sufficiently regulated by medication. DBS is achieved by surgically implanting a battery-operated neurostimulator device, to deliver electrical impulses to the areas of the brain that control movement, blocking the abnormal nerve signals that cause the tremors associated with Parkinson's.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel